Lymphoma News

The Gloucester Pharmaceuticals drug Istodax has been approved by the U.S. Food and Drug Administration to treat cutaneous T-cell lymphoma in people who have tried at least one prior systemic therapy, the drug's manufacturer said in a news release.

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Sunesis Pharmaceuticals, Inc.

A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.

The U.S. Food and Drug Administration has approved a lymphoma drug developed by privately held biotechnology firm Gloucester Pharmaceuticals .

New data published today in the journal, Cancer , reveals that three quarters of patients with indolent B-cell non-Hodgkin's lymphoma , responded to treatment with Bendamustine following a single-arm, multicentre study.

The end of cancer treatment and court hearings could be in sight for Sleepy Eye teen Daniel Hauser.

Main Category: Stem Cell Research Also Included In: Lymphoma / Leukemia / Myeloma Article Date: 06 Nov 2009 Stem Cell Therapy International Inc.

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer .

A pillar of Hastings' athletic community has been denied funding for a trial cancer drug which could save his life.

Gloria Full lives in a comfortable home in Ahwatukee Foothills. It is filled with cards, flowers and pictures of her family.

Main Category: Stem Cell Research Also Included In: Blood / Hematology ; Conferences Article Date: 03 Nov 2009 - 1:00 PST At a symposium today in Herzliya entitled Umbilical Cord Blood: An Alternative for Bone Marrow Transplantation in Adults, bone marrow transplantation experts Professor Patrick Stiff and Professor Guillermo Sanz addressed ...

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer NOX-A12. NOX-A12 is NOXXON's second drug candidate entering the clinical stage of ...

Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Childrena s ...

Cancer is a word you never want a doctor to say to you. When you're older, it's traumatic enough, but when you're young and still thinking about your whole life and future family, it is devastating.

Cellphone radiation, clock radios can act as catalysts for cancer An Australian brain cancer surgeon has called upon people to use mobile phones and clock radios with caution as, according to him, they are catalysts for cancer.

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue.

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.

Few showers. Low 52. FRIDAY: Mostly cloudy, breezy & mild. Few showers, mainly northwest of Columbus.

E-mail: weili_zhao_sih@yahoo.com Received 28 June 2009; Revised 22 August 2009; Accepted 28 August 2009; Published online 29 October 2009.

Background The risk of development of non-Hodgkin lymphoma in autoimmune patients has been investigated in several cohort studies.